Author

Michael Chiorean

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

Michael Chiorean  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Michael Chiorean  et al.

RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Michael Chiorean  et al.

LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
LONG-TERM CLINICAL AND ENDOSCOPIC OUTCOMES IN TRUE NORTH WEEK 52 CLINICAL REMITTERS OVER 3 YEARS OF TREATMENT WITH OZANIMOD: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Michael Chiorean  et al.

MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL

Michael Chiorean  et al.

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND SUBSTUDY

Michael Chiorean  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Michael Chiorean  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Michael Chiorean  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Michael Chiorean  et al.

Item 1 - 11 / 11
1